Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of alpha-interferon treatment.
Platelet aggregability and some biochemical parameters were evaluated in seven patients with essential thrombocythemia (ET) compared with seven patients with secondary thrombocytosis (ST). Defective platelet aggregation with one or more agonists was seen in five patients with ET whereas aggregation was increased in two other patients. In addition, three patients with ET demonstrated spontaneous platelet aggregation in citrated plasma. This was associated with increased level of thrombospondin (TSP) in the plasma membrane. Interestingly, the presence of a proteolyzed 160 kDa form of TSP was detected in all patients with ET, whereas it was never found in patients with ST. Furthermore, three patients with ET demonstrated increased levels of platelet surface glycoprotein IV (GP IV), the putative receptor for TSP in the plasma membrane. In two of these patients, this correlated with increased surface expression of TSP and spontaneous platelet aggregation. The results suggest a possible link between the increased number of plasma membrane GP IV molecules, the spontaneous expression of TSP on the platelet surface and platelet hyperaggregability in some ET patients. The levels of plasma membrane GP IV and platelet surface-associated TSP tended to be normalized during alpha-interferon treatment, whereas the presence of an altered form of TSP persisted. This last parameter might be of practical usefulness in the characterization of the disease, permitting a clear distinction from ST.
Legrand
C
C
INSERM U 150/Laboratoire Association Claude Bernard et Département d'Angiohématologie, IVS, Hôpital Lariboisière, Paris, France.
Bellucci
S
S
Disdier
M
M
Edelman
L
L
Tobelem
G
G
D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D001792:Blood Platelets / Q000502:physiology; D018955:CD36 Antigens; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D010976:Platelet Count; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000378:metabolism* / Q000628:therapy; D013922:Thrombocytosis / Q000378:metabolism*; D019699:Thrombospondins
D015703:Antigens, CD; D018955:CD36 Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010980:Platelet Membrane Glycoproteins; D011994:Recombinant Proteins; D019699:Thrombospondins